2023
DOI: 10.2196/41050
|View full text |Cite
|
Sign up to set email alerts
|

Characterization of Influenza-Like Illness Burden Using Commercial Wearable Sensor Data and Patient-Reported Outcomes: Mixed Methods Cohort Study

Abstract: Background The burden of influenza-like illness (ILI) is typically estimated via hospitalizations and deaths. However, ILI-associated morbidity that does not require hospitalization remains poorly characterized. Objective The main objective of this study was to characterize ILI burden using commercial wearable sensor data and investigate the extent to which these data correlate with self-reported illness severity and duration. Furthermore, we aimed to d… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 35 publications
(44 reference statements)
0
1
0
Order By: Relevance
“…Patient-reported outcomes are important tools in real-world studies to comprehensively capture a patient’s disease experience and are useful in assessing the impact of the disease and subsequent therapeutic approaches [ 19 , 20 ]. This prospective, noninterventional survey study aimed to describe household transmission and healthcare resource utilization among patients with influenza who filled a prescription for baloxavir vs oseltamivir in the USA.…”
Section: Introductionmentioning
confidence: 99%
“…Patient-reported outcomes are important tools in real-world studies to comprehensively capture a patient’s disease experience and are useful in assessing the impact of the disease and subsequent therapeutic approaches [ 19 , 20 ]. This prospective, noninterventional survey study aimed to describe household transmission and healthcare resource utilization among patients with influenza who filled a prescription for baloxavir vs oseltamivir in the USA.…”
Section: Introductionmentioning
confidence: 99%